Capricor Therapeutics

News

FDA advisors vote no to Capricor's DMD therapy

FDA advisors voted that Capricor has not shown efficacy for deramiocel in Duchenne muscular dystrophy, due to altered endpoints in its main trial.

News

Capricor sues partner Nippon Shinyaku in DMD therapy spat

Capricor has filed a lawsuit seeking to split from its commercial partner for Duchenne muscular dystrophy therapy, deramiocel, in the US.

News

Capricor files cell therapy for DMD cardiomyopathy with FDA

Capricor completes its US filing for deramiocel, vying to become the first FDA-approved therapy for cardiomyopathy in Duchenne muscular dystrophy.

News

Young lonely man in a wheelchair on a balcony looking at the nature in the spring

Capricor preps phase 3 for Duchenne cell therapy as it seeks...

Capricor Therapeutics' bid to find a partner for its Duchenne muscular dystrophy (DMD) cell therapy CAP-1002 could get a boost after final phase 2 data showed a strong effect on disease pro

FDA advisors vote no to Capricor's DMD therapy

Capricor sues partner Nippon Shinyaku in DMD therapy spat

Capricor files cell therapy for DMD cardiomyopathy with FDA

Capricor preps phase 3 for Duchenne cell therapy as it seeks...

Ex-BioNTech execs launch 'AI-native' cancer company

Discover a new era of healthcare panel engagement: Grounded ...

Capricor Therapeutics

Editor's Picks